lapatinib has been researched along with dinaciclib in 2 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (dinaciclib) | Trials (dinaciclib) | Recent Studies (post-2010) (dinaciclib) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 133 | 12 | 129 |
| Protein | Taxonomy | lapatinib (IC50) | dinaciclib (IC50) |
|---|---|---|---|
| Cyclin-T1 | Homo sapiens (human) | 0.0272 | |
| Cyclin-K | Homo sapiens (human) | 0.0227 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.0162 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.0742 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.049 | |
| Cyclin-A2 | Homo sapiens (human) | 0.002 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.119 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.0028 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.0074 | |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | 0.23 | |
| Cyclin-dependent kinase 8 | Homo sapiens (human) | 0.0039 | |
| Glycogen synthase kinase-3 alpha | Homo sapiens (human) | 0.414 | |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | 0.324 | |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | 0.1273 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 0.0227 | |
| Cyclin-H | Homo sapiens (human) | 0.17 | |
| CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | 0.17 | |
| Cyclin-A1 | Homo sapiens (human) | 0.003 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.011 | |
| Heat shock factor protein 1 | Homo sapiens (human) | 0.007 | |
| Cyclin-dependent kinase 13 | Homo sapiens (human) | 0.021 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.0219 | |
| Cyclin-dependent kinase 12 | Homo sapiens (human) | 0.0323 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Li, C; Li, H; Lin, F; Ma, F; Nan, P; Qian, H; Wang, H; Wang, J; Wang, T; Xu, D; Yi, Z; Zhang, J | 1 |
2 other study(ies) available for lapatinib and dinaciclib
| Article | Year |
|---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cyclic N-Oxides; Cyclin-Dependent Kinases; Databases, Genetic; Drug Resistance, Neoplasm; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Indolizines; Lapatinib; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinase; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridinium Compounds; Receptor, ErbB-2; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |